Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
Alkermes (ALKS) CEO Richard Jackson announced six clinical readouts expected in the next 12 months, including Phase 3 studies for narcolepsy and a Phase 2 study for ADHD drug ALKS 7290. The company also expects to file LUMRYZ, its narcolepsy treatment, and discussed its commercial strategy for VIVITROL and LYBALVI, citing patent protection and manufacturing challenges for potential competitors.


